British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

With the AI revolution underway, sustainability is now a key consideration for pharma companies building and utilising data centres.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of AD, including the clinical progression of its lead candidate, ...

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.